Maria Fernanda Zuliani Mauro, MD1; J. Armando Mangione, MD1; J. Ribamar Costa, Jr, MD2; Ricardo Costa, MD2; Luiz Alberto Piva e Mattos, MD2; Rodolfo Staico, MD2; Fausto Feres, MD2; Dimytri Siqueira, MD2; Amanda Sousa, MD2; Alexandre Abizaid, MD2
Maria Fernanda Zuliani Mauro, MD1; J...
This prospective, placebo-controlled trial was conducted in diabetic patients randomized (1:1) to receive either standard DAPT vs TAPT with cilostazol for a minimum of 12 months after PCI with Endeavor zotarolimus-eluting stent.
This prospective, placebo-controlled trial was conducted in diabetic patients randomized (1:1) to receive either standard DAPT vs TAPT with cilostazol for a minimum of 12 months after PCI with Endeavor zotarolimus-eluting stent.